GLYBERA Trademark

Trademark Overview

On Friday, May 11, 2007, a trademark application was filed for GLYBERA with the United States Patent and Trademark Office. The USPTO has given the GLYBERA trademark a serial number of 77179356. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, January 12, 2018. This trademark is owned by AMSTERDAM MOLECULAR THERAPEUTICS (AMT) BV. The GLYBERA trademark is filed in the Pharmaceutical Products category with the following description:

Biological preparations for medical use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapy, gene diagnosis, and gene testing; pharmaceutical preparations, namely, vaccines for use in gene therapy; gene therapy and prophylaxis products, namely, gene-based biological preparations and medical reagents for use in gene regulation and gene modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, cancer, inflammatory and auto-immune diseases, vascular disorders, and single gene disorders
glybera

General Information

Serial Number77179356
Word MarkGLYBERA
Filing DateFriday, May 11, 2007
Status710 - CANCELLED - SECTION 8
Status DateFriday, January 12, 2018
Registration Number3972244
Registration DateTuesday, June 7, 2011
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 22, 2011

Trademark Statements

Goods and ServicesBiological preparations for medical use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapy, gene diagnosis, and gene testing; pharmaceutical preparations, namely, vaccines for use in gene therapy; gene therapy and prophylaxis products, namely, gene-based biological preparations and medical reagents for use in gene regulation and gene modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, cancer, inflammatory and auto-immune diseases, vascular disorders, and single gene disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, January 12, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameUNIQURE IP B.V.
Party Type32 - New Owner After Registration
Legal Entity Type99 - Other
AddressAMSTERDAM NL-1105BA
NL
Party NameAMSTERDAM MOLECULAR THERAPEUTICS (AMT) IP B.V.
Party Type31 - New Owner After Registration
Legal Entity Type99 - Other
AddressAMSTERDAM NL-1105BA
NL
Party NameAMSTERDAM MOLECULAR THERAPEUTICS (AMT) BV
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressAmsterdam NL-1105BA
NL
Party NameAMSTERDAM MOLECULAR THERAPEUTICS (AMT) BV
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressAmsterdam NL-1105BA
NL
Party NameAMSTERDAM MOLECULAR THERAPEUTICS (AMT) BV
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressAmsterdam NL-1105BA
NL

Trademark Events

Event DateEvent Description
Friday, January 12, 2018CANCELLED SEC. 8 (6-YR)
Wednesday, August 15, 2012AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, September 14, 2011AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, June 7, 2011REGISTERED-PRINCIPAL REGISTER
Tuesday, March 22, 2011PUBLISHED FOR OPPOSITION
Wednesday, March 2, 2011NOTICE OF PUBLICATION
Wednesday, February 16, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, February 14, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 24, 2011TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 24, 2011CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 18, 2011TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 27, 2010NON-FINAL ACTION MAILED
Thursday, August 26, 2010NON-FINAL ACTION WRITTEN
Friday, July 30, 2010LIE CHECKED SUSP - TO ATTY FOR ACTION
Thursday, January 28, 2010LETTER OF SUSPENSION MAILED
Wednesday, January 27, 2010SUSPENSION LETTER WRITTEN
Wednesday, January 27, 2010DATA MODIFICATION COMPLETED
Thursday, November 26, 2009TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 25, 2009CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 25, 2009TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, November 18, 2009FAX RECEIVED
Monday, June 22, 2009INQUIRY AS TO SUSPENSION MAILED
Friday, June 19, 2009SUSPENSION INQUIRY WRITTEN
Friday, June 5, 2009LIE CHECKED SUSP - TO ATTY FOR ACTION
Friday, December 5, 2008LETTER OF SUSPENSION MAILED
Friday, December 5, 2008SUSPENSION LETTER WRITTEN
Tuesday, November 18, 2008TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 18, 2008CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 14, 2008TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, May 22, 2008NON-FINAL ACTION MAILED
Thursday, May 22, 2008NON-FINAL ACTION WRITTEN
Thursday, April 17, 2008AMENDMENT FROM APPLICANT ENTERED
Thursday, April 17, 2008CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 17, 2008ASSIGNED TO LIE
Wednesday, April 16, 2008PAPER RECEIVED
Tuesday, March 4, 2008ASSIGNED TO EXAMINER
Tuesday, November 27, 2007LETTER OF SUSPENSION MAILED
Tuesday, November 27, 2007SUSPENSION LETTER WRITTEN
Tuesday, November 6, 2007TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 6, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 6, 2007TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 28, 2007NON-FINAL ACTION MAILED
Monday, August 27, 2007NON-FINAL ACTION WRITTEN
Thursday, August 23, 2007ASSIGNED TO EXAMINER
Thursday, May 17, 2007NEW APPLICATION ENTERED IN TRAM

Related Keywords

glybera gene disorders therapy medical preparations diseases reagents biological clinical namely